Type II hyaluronic acid synthetase mutant and construction method thereof

By mutations in specific regions of type II hyaluronic acid synthetase, the catalytic activity of the enzyme is improved, and the problem of insufficient transformation of type II enzymes in the prior art is solved, and high efficiency and high yields in E. coli and Corynebacterium glutamicum Hyaluronic acid synthesis has achieved co-evolution of HA yield and molecular weight.

CN118879658APending Publication Date: 2024-11-01CHANGZHOU INST OF MATERIA MEDICA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410971511.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

In the prior art, the genetic engineering of hyaluronic acid synthetase is mainly concentrated on type I enzymes, and type II enzymes are less modified, resulting in a low yield of high molecular weight hyaluronic acid, making it difficult to achieve industrial production.

Method used

Mutations such as P153S, P153D and G312S are obtained by mutating the amino acid sequences of type II hyaluronan synthetase of polyoxic Pasteurium to improve the catalytic activity of the enzyme by mutations in the region 150-155, 310-313 or 639-643 of the type II hyaluronan synthetase of polyoxic Pasteurium to obtain mutants, such as P153S, P153D and G312S, to improve the catalytic activity of the enzyme. , construct recombinant plasmids and introduce them into E. coli or Corynebacterium glutamicum to achieve high yield and high molecular weight hyaluronic acid synthesis.

Benefits of technology

The HA production of mutants in E. coli and Corynebacterium glutamicum increased by 2 to 6.8 times and the molecular weight increased by 2 to 63.8 times, significantly increasing the yield and molecular weight of hyaluronic acid and realizing the industrial production potential of HA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879658A_ABST
    Figure CN118879658A_ABST
Patent Text Reader

Abstract

The invention discloses a type II hyaluronic acid synthetase mutant and a construction method thereof, and belongs to the technical field of gene engineering. The catalytic activity of the hyaluronic acid synthetase derived from pasteurella multocida is improved through a protein modification method based on semi-rational design of molecular dynamics simulation, the yield of hyaluronic acid can be increased by converting the hyaluronic acid synthetase into escherichia coli or corynebacterium glutamicum, and meanwhile, the molecular weight is remarkably increased. Coevolution of HA yield and molecular weight is realized for the first time, anabolism pathways of HA are respectively constructed in escherichia coli and corynebacterium glutamicum, and the method has a good industrial application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a type II hyaluronan synthase mutant and a construction method thereof. Background Art

[0002] Hyaluronic acid (HA) is a linear, unbranched macromolecular mucopolysaccharide formed by repeated cross-linking of disaccharide units consisting of β-D-glucuronic acid (GlcA) and β-DN-acetylglucosamine (GlcNAc), in which GlcA and GlcNAc are linked by β-1,3 glycosidic bonds to form a disaccharide unit, and GlcNAc is linked to GlcA in the next disaccharide unit by a β-1,4 bond.

[0003] HA is widely present in the human body and has unique physiological functions and application value. Its powerful water-locking ability can help the skin retain moisture and make the skin look softer and plumper. At the same time, HA is the main component of synovial fluid and has shock-absorbing and lubricating effects, which can reduce joint wear and promote joint health. HA is also widely used in the field of beauty. For example, injecting HA can cause skin congestion and promote cell metabolism, and improve skin texture or bumps. High molecular weight HA has good viscoelasticity and moisturizing properties and can be used in ophthalmic and orthopedic surgery. In short, due to its unique physiological functions and wide application value, HA has important application prospects in many fields such as medicine, cosmetics and food.

[0004] The main methods for preparing HA include tissue extraction and microbial fermentation. The raw materials of tissue extraction are animal tissues, such as chicken combs, etc. This method is complex, the product extraction rate is only about 1%, and the production cost is high. At the same time, HA from animal sources may have the risk of immunogenicity; microbial fermentation mainly produces HA through microbial fermentation. Streptococcus zooepidemicus, Streptococcus equi and other streptococcal hosts contain a complete metabolic pathway for synthesizing HA, but the HA yield is usually low. At the same time, this type of bacteria has certain pathogenicity, especially the hemolysin S produced by streptococci can damage the cell membrane and cause cell hemolysis. In order to improve the production process of HA and the safety of HA products, metabolic engineering technology for heterologous synthesis of HA pathways came into being.

[0005] In recent years, there have been more and more reports on the synthesis of HA through metabolic engineering technology. For example, Winder introduced hasA and several genes related to precursor synthesis into Bacillus subtilis and successfully constructed an engineered bacterium for HA production (Applied and environmental microbiology, 2005, 71, 3747-3752); Mao et al. introduced hyaluronan synthase (PmHAS) and UDP-glucose dehydrogenase genes of E. coli K5 strain into E. coli JM109 and produced HA by fermentation, with a yield of 2.0-3.8 g·L -1 (Applied microbiology and biotechnology, 2009, 84, 63-69); Jeong et al. successfully synthesized high molecular weight HA using hyaluronan synthase (xlHasA) of African clawed frog in Pichia pastoris (Journal of biotechnology, 2014, 185, 28-36); Gomes et al. first combined the hasA gene of Pasteurella multocida with the hasB gene of African clawed frog in Kluyveromyces lactis to express HA synthesis (Microorganisms, 2019, 7, 294).

[0006] The key factors for heterologous synthesis of HA are the synthesis pathway of HA precursors (UDP-GlcA and UDP-GlcNAc) and the hyaluronan synthase gene. Most hosts have the relevant enzymes for the synthesis of the two precursor pathways, but the expression levels vary. Therefore, whether or not there is hyaluronan synthase is the key to determining whether the host can synthesize hyaluronan.

[0007] Hyaluronan synthase (HAS) is a class of highly efficient bifunctional glycosyltransferases that catalyze the transfer reaction of glucuronic acid and N-acetylglucosamine simultaneously. According to the amino acid sequence homology and topological structure, HAS can be divided into Class I and Class II. The sources of Class I enzymes include Streptococcus S. pyogenes (SpHAS), S. equisimilis (SeHAS), S. zooepidemicus (SzHAS), S. parauberis (SpaHAS) and S. uberis (SuHAS), as well as viral PBCV-1 (CvHAS) and HAS enzymes from vertebrates; the only member of Class II is PmHAS from Pasteurella multocida, which consists of three independent functional regions: the amino acid residues 1 to 703 constitute the catalytic region of glucosamine and glucuronyl transferase; the amino acid residues 704 to 972 are the anchoring region of the cell membrane phospholipid bilayer and do not participate in the catalytic process of glycosyl transfer reaction.

[0008] In summary, under the premise of ensuring that the two precursors of HA (UDP-GlcA and UDP-GlcNAc) are sufficient and balanced, improving the catalytic activity of hyaluronan synthase becomes the core issue of increasing HA production. In recent years, there have been many reports on genetic engineering of type I hyaluronan synthase, but there are few reports on genetic engineering of type II hyaluronan synthase. There are only a few reports on the transformation of PmHAS to obtain high molecular weight HA. For example, John Mandawe et al. used error-prone PCR and KnowVolution strategy to screen and obtain the mutant T40L / V59M / T104A that can make the HA molecular weight reach 4.7MDa, but its HA production is only 0.26g·L -1 High molecular weight HA is certainly important, but low yield will inevitably increase production costs, making it difficult to achieve true industrial production. Therefore, improving the catalytic activity of HAS through protein engineering and thus increasing HA yield, while increasing HA molecular weight, is the key to achieving industrial production of HA synthesized by microbial methods. Summary of the invention

[0009] The present invention aims to provide a method for improving the hyaluronic acid production of Escherichia coli and Corynebacterium glutamicum by using a type II hyaluronic acid synthase mutant.

[0010] One aspect of the present invention provides a type II hyaluronan synthase mutant, which is obtained by mutating any one or several sites in the three regions of 150-155, 310-313 or 639-643 on the amino acid sequence of PmHAS.

[0011] Type II hyaluronan synthase, hereinafter referred to as hyaluronan synthase refers to type II hyaluronan synthase,

[0012] Furthermore, the mutant is obtained by mutating any one or several of the K152, P153, G312, E313, N642 or T643 sites.

[0013] Furthermore, the mutant is any one of P153S, P153D or G312S.

[0014] Another aspect of the present invention provides a gene encoding the above-mentioned hyaluronan synthase mutant.

[0015] Another aspect of the present invention provides a plasmid, wherein the plasmid contains the above gene. The plasmid may be pXMJ19 or pECXK99E, or other plasmids commonly used in the art.

[0016] Another aspect of the present invention provides a bioengineering bacterium containing or integrating the above-mentioned plasmid.

[0017] Furthermore, the bioengineering bacteria is Escherichia coli or Corynebacterium glutamicum.

[0018] Another aspect of the present invention provides the use of the above-mentioned type II hyaluronan synthase mutant, gene, plasmid or bioengineering bacteria in the preparation of hyaluronic acid.

[0019] Another aspect of the present invention provides a method for preparing hyaluronic acid using type II hyaluronic acid synthase, which comprises constructing a bioengineering bacterium containing a target gene, culturing and fermenting the bioengineering bacterium, and obtaining a fermentation product. The target gene is obtained by mutating any one or more sites in the three regions of 150-155, 310-313 or 639-643 on the PmHAS amino acid sequence.

[0020] Furthermore, the target gene is obtained by mutating any one or more sites of K152, P153, G312, E313, N642 or T643 on the PmHAS amino acid sequence.

[0021] Furthermore, the target gene is obtained by any mutation of P153S, P153D or G312S in the amino acid sequence of PmHAS.

[0022] The bioengineering bacteria described in this article are Escherichia coli or Corynebacterium glutamicum.

[0023] Furthermore, the method for obtaining the bioengineering bacteria is to introduce a recombinant plasmid containing a mutant into the bioengineering bacteria. The plasmid may be a plasmid commonly used in the art, for example, a plasmid provided in the examples of the specification of this document may be used.

[0024] Furthermore, the PCR amplification primers for the mutant are shown in Table 2.

[0025] Furthermore, the culture and fermentation method adopts a culture and fermentation method commonly used in the art. Specifically, it includes: inoculating the strain into a culture medium to obtain a seed culture solution, and then inoculating the seed culture solution into a fermentation medium for fermentation. It can also be a method described in the embodiments of the specification of this article.

[0026] As described above, the hyaluronan synthase mutants and applications thereof of the present invention have the following beneficial effects:

[0027] Through molecular dynamics simulation of PmHAS, it was found that the RMSF values ​​of the three regions of 150-155, 310-313 and 639-643 fluctuated significantly, which may be the key regions affecting enzyme activity. Mutation of sites in these three regions may increase HA production. Through genetic modification, we have obtained a large number of hyaluronan synthase mutants. On this basis, the more preferred mutants are P153S, P153D and G312S, which increase HA production to 2-2.4 times that of the wild type and increase the molecular weight to 2-4 times that of the wild type. Among them, when G312S was introduced into Corynebacterium glutamicum and fermented in a tank, the HA production increased to 6.8 times that of the wild type and the molecular weight increased to 63.8 times that of the wild type. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The average conformation of PmHAS α RMSF value

[0029] Figure 2 pXMJ19-PmHAS plasmid map

[0030] Figure 3 SDS-PAGE analysis of PmHAS

[0031] Figure 4 Comparison of the production of hyaluronic acid synthesized by Escherichia coli hosts with different backgrounds

[0032] Figure 5 Construction of NNK saturation mutation gene library by whole plasmid PCR

[0033] Figure 6 NNK saturation mutagenesis transformant library

[0034] Figure 7 Preliminary results of high-throughput screening of saturation mutation library

[0035] Figure 8 Results of rescreening of saturation mutation library

[0036] Fig. 9 PCR amplification of mutant genes

[0037] Fig.10 Sequencing results of mutants

[0038] Fig.11 Comparison of HA production by shake flask fermentation of the best mutants

[0039] Fig.12 Construction of mutant plasmid by whole plasmid PCR

[0040] Fig.13 Electroporation of mutant plasmid into Corynebacterium glutamicum ATCC13032

[0041] Fig.14 Comparison of hyaluronic acid production in recombinant Corynebacterium glutamicum containing different PmHAS mutant plasmids DETAILED DESCRIPTION

[0042] There is no report on the crystal structure of PmHAS. The protein structure of PmHAS can only be obtained through homology modeling to guide the subsequent semi-rational experimental design. The template was obtained by inputting the sequence into the Swiss-model website for comparison and screening. The chondroitin polymerase (K4CP) from Escherichia coli K4 with a sequence similarity of 62% to PmHAS was selected as the template. The PDB accession number is: 2z86. The structure is a homodimer and contains the ligands UGA and UDP. The crystal resolution is use The software was used to model the single subunit structure, and the credibility of the structure was evaluated by GMQE evaluation and pull-type structural analysis. After obtaining a reliable protein tertiary structure, molecular dynamics simulation was performed using Gromacs2019, and the protein structure C was extracted after the simulation. α The RMSD and RMSF values ​​of the simulation are shown in Table 1. The RMSD value represents the structural deviation relative to the reference conformation at a certain moment. As the simulation time increases, when the fluctuation of the RMSD value is less than The simulated structure is considered to have reached a good balance, and the final conformation or average conformation can be extracted for subsequent analysis; the RMSF value represents the structural change of an atom relative to the reference conformation, reflecting the freedom of the atom. α The RMSF value of the structure can be used to quickly obtain the significantly flexible regions in the structure. These regions may be involved in the catalytic reaction and can be used as key mutation regions. The present invention extracts and analyzes the RMSF value of the average conformation, such as Figure 1, we found that the RMSF values ​​of the three regions of 150-155, 310-313 and 639-643 fluctuated significantly. By analyzing the structure, we found that these structures were all located in the loop region, of which 150-155 was located in the loop region at the junction of the two catalytic domains, 310-313 was located at the entrance of the substrate channel of the catalytic center of GlcNAC transferase, and 639-643 was located near the catalytic center of GlcA transferase, close to the substrate binding region. In summary, these regions may be related to the catalytic activity of hyaluronan synthase, so we believe that these three regions are key mutation regions. In order to quickly screen the key sites that affect enzyme activity, we preferentially selected the K152, P153, G312, E313, N642 and T643 sites with the largest RMSF value fluctuations in these three regions for the construction of the mutation library, and used NNK degenerate primers for the construction of the saturation mutation library.

[0043] Definition of terms

[0044] Herein, the term "bioengineering bacteria" refers to those cells that are used to transform, i.e., the cell that is used to express the target gene. Bioengineering bacteria can be a cell line cultivated in an isolated cell or culture, or a cell that is present in a living tissue or an organism. In the context of the present invention, host cells are preferably cells that can grow in culture. The cell described in the present invention is a bacterium or a fungus, and the present invention carries out embodiment demonstration and description with Escherichia coli and Corynebacterium glutamicum.

[0045] The following is an explanation of the embodiments of the present invention by specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the process equipment or devices not specifically noted in the following embodiments all adopt conventional equipment or devices in the art. In addition, it should be understood that one or more method steps mentioned in the present invention do not exclude the presence of other method steps before and after the combination step or the insertion of other method steps between these explicitly mentioned steps, unless otherwise specified; it should also be understood that the combined connection relationship between one or more devices / devices mentioned in the present invention does not exclude the presence of other devices / devices before and after the combination device / device or the insertion of other devices / devices between these explicitly mentioned two devices / devices, unless otherwise specified. Moreover, unless otherwise specified, the numbering of each method step is only a convenient tool for identifying each method step, rather than limiting the order of arrangement of each method step or limiting the scope of the present invention. The change or adjustment of its relative relationship, without substantial change in the technical content, should also be regarded as the scope of the present invention.

[0046] Example 1 Construction of recombinant plasmid pXMJ19-PmHAS

[0047] The hyaluronan synthase gene PmHAS from Pasteurella multocida was selected, with GenBanK accession number: AF036004.2, a gene length of 2920bp, encoding 972 amino acids, of which amino acids 1 to 703 constitute the catalytic region of glucosamine and glucuronyl transferase, and amino acids 704 to 972 are the anchoring region with the cell membrane phospholipid bilayer, which does not participate in the catalytic process of the glycosyl transfer reaction. Removing the cell membrane anchoring region sequence can achieve soluble expression of PmHAS in the cytoplasm of the engineered bacteria and obtain a protein with complete catalytic activity. Therefore, amino acid residues 1 to 703 were selected for gene synthesis and vector construction. This part of the work was completed by General Bio (Anhui) Co., Ltd., and finally the pXMJ19-PmHAS plasmid was obtained. The plasmid map is shown in FIG. Figure 2 shown.

[0048] Example 2 Expression verification of PmHAS in Escherichia coli

[0049] The plasmid pXMJ19-PmHAS and the control plasmid pXMJ19 synthesized by gene were transformed into E. coli BL21 (DE3) competent cells, and the transformants were cultured and induced for expression verification. The results are as follows: Figure 3 As shown in the figure, compared with the control bacteria, in the supernatant of the recombinant engineering bacteria E. coli BL21 / pXMJ19-PmHAS, an obvious protein band can be observed between 70 and 100 KDa, which is consistent with the theoretical molecular weight (80.7 KDa) corresponding to the synthesized PmHAS sequence, indicating that the codon-optimized sequence can be successfully expressed in the Escherichia coli host.

[0050] Example 3 Construction of recombinant Escherichia coli with different backgrounds and comparison of the yield of synthesized hyaluronic acid

[0051] By searching the metabolic pathway of E.coli BL21 through KEGG pathway, it was found that the host contains enzymes for the metabolic pathway of synthesizing hyaluronic acid unit precursors UDP-GlcA and UDP-GlcNAc, but does not contain hyaluronic acid synthase, so it cannot biosynthesize HA. By introducing a heterologous hyaluronic acid synthase gene, a complete metabolic pathway for synthesizing HA can be constructed in E. coli.

[0052] Furthermore, the metabolic pathway for synthesizing UDP-GlcA includes: starting from glucose, glucose-6-phosphate is generated under the action of glucose kinase (glk), and then glucose-1-phosphate is generated under the action of glucose phosphoglucomutase (pgm), and the latter is catalyzed by glucose 1-phosphate uridyltransferase (galU) to generate UDP-glucose (UDP-Glc), and finally UDP-glucuronate (UDP-GlcA) is generated under the action of UDP-glucose-6-phosphate-dehydrogenase (ugd).

[0053] Further, the metabolic pathway for synthesizing UDP-GlcNAc includes: starting from glucose, glucose-6-phosphate is generated under the action of glucokinase (glk), and then fructose-6-phosphate is generated under the action of glucose phosphoisomerase (pgi), the latter is generated under the action of L-glutamine / fructose-6-phosphate aminotransferase to generate glucosamine-6-phosphate (glmS), and then glucosamine-1-phosphate is generated under the action of phosphoglucosamine mutase (glmM), and then N-acetylglucosamine-1-phosphate is generated under the action of bifunctional enzyme N-acetyl-glucosamine-1-phosphate uridyltransferase and glucosamine-1-phosphate acetyltransferase or bifunctional UDP-N-acetylglucosamine pyrophosphorylase / glucosamine-1-phosphate-N-acetyltransferase (glmU), and finally UDP-N-acetyl-glucosamine (UDP-GlcNAc) is generated under the action of bifunctional UDP-N-acetylglucosamine pyrophosphorylase / glucosamine-1-phosphate-N-acetyltransferase (glmU).

[0054] The plasmid pXMJ19-PmHAS obtained by gene synthesis is transformed into E.coli BL21 (DE3) competent cells, and recombinant bacteria E.coli BL21 (DE3) / pXMJ19-PmHAS can be obtained after culture. Since the two precursors of HA are synthesized in vivo, the amount of the precursors may not be sufficient to meet the detection level of HA. In order to increase the synthesis amount of the two precursors, the present invention constructs vectors pECXK99E-ugd and pECXK99E-ugd-glmU that overexpress ugd and ugd-glmU genes, respectively, and transforms them into E.coli BL21 (DE3) / pXMJ19-PmHAS competent cells, and obtains E.coliBL21 (DE3) / pXMJ19-PmHAS / pECXK99E-ugd and E.coli BL21(DE3) / pXMJ19-PmHAS / pECXK99E-ugd-glmU.

[0055] After obtaining the above recombinant bacteria, shake flask fermentation was performed to compare the levels of HA synthesis of these strains. The culture medium was LBG medium: peptone 10 g·L -1 , yeast extract 5g·L -1 , sodium chloride 10g·L -1 , glucose 20g·L -1 Glucose was added after 24 h of induction, and the initial and seed culture medium was LB medium: peptone 10 g L -1 , yeast extract 5g·L -1 , sodium chloride 10g·L -1 The specific experimental steps are as follows: the above recombinant bacteria were streaked onto LB solid plates containing the corresponding antibiotic concentrations, cultured at 37°C, 220rpm overnight, and a single colony was picked up the next day and inoculated into 30mL LB liquid culture medium. After culturing at 37°C, 220rpm for 8-10h, 3% inoculation was inoculated into 30mL LB liquid culture medium, and cultured at 37°C, 220rpm for 2-3h, and then the OD 600 When the concentration reached 0.8-1.0, IPTG was added to induce the mixture at a final concentration of 0.5 mM. After culturing at 30°C and 220 rpm for 24 h, 20 g·L -1 The culture medium was then cultured at 30°C, 220 rpm for 42-48 h for the synthesis of HA. After the fermentation was completed, the yield and molecular weight of HA were determined.

[0056] Since the hyaluronan synthase from Pasteurella multocida is a type II synthase, it relies on the host's own ABC transport system to achieve HA secretion. However, Escherichia coli and Corynebacterium glutamicum do not have this transport system, which will cause HA to accumulate in the cell and cannot be secreted normally. Therefore, HA is mainly distributed in the cell and needs to be extracted for determination of HA molecular weight.

[0057] Extraction reagents for intracellular HA:

[0058] Solution I: 25mM Tris-HCl, 10mM EDTA, 20mg·mL -1 Lysozyme, pH 8.0;

[0059] Solution II: 0.2M NaOH, 1% SDS;

[0060] Solution III: 3M KOAC, pH 6.0;

[0061] DNase buffer solution: 1 mg mL -1 DNase, 10mM Tris-HCl pH 7.5, 2.5mM MgCl2, 0.5mMCaCl2;

[0062] CTAB solution: 2.5 g·L -1 CTAB, dissolved in 2% NaOH;

[0063] Extraction method of intracellular HA:

[0064] Take 2mL of the above fermentation broth in a 5.0mL centrifuge tube, centrifuge at 12000rpm for 2min, discard the supernatant, add 750μL Solution I solution to the obtained precipitate, and react at 37℃, 220rpm for 1h; then add 750μL Solution II solution and mix gently to completely lyse the cells, continue to add 1050μL Solution III to neutralize the precipitation reaction, invert several times to mix, place in a centrifuge, centrifuge at 12000rpm for 10min, aspirate all the supernatant into a 50mL centrifuge tube, and add 10mL of anhydrous ethanol to the centrifuge tube, then put it in -20℃ overnight precipitation, centrifuge at 4℃, 8000rpm for 10min the next day, discard the supernatant, place the precipitate in a drying oven to dry, and add 2mL DNase buffer solution to resuspend the precipitate after drying, and perform HA concentration detection.

[0065] HA concentration detection principle: The HA concentration was determined by the modified CTAB turbidimetric method. The principle of this method is that hexadecyltrimethylammonium bromide (CTAB) can react with HA to produce flocculent turbidity and follow the Lambert-Beer law within a certain concentration range (Establishment of CTAB Turbidimetric method to determine hyaluronic acid content in fermentation broth Carbohydr. Polym, 2009).

[0066] HA concentration detection method: Take 100 μL of the above sample into a 96-well ELISA plate, add 200 μL CTAB (2.5 g·L -1 , 2% NaOH), and then placed on a microplate reader immediately after slight shaking, and the absorbance was measured at 400 nm. The concentration of HA was calculated based on the standard curve of hyaluronic acid.

[0067] Hyaluronic acid standard curve:

[0068] According to Table 1, 0, 25, 50, 125, 250, 500, 750, 1000 mg·L -1 Hyaluronic acid solution.

[0069] Table 1 Preparation of hyaluronic acid standard curve

[0070]

[0071] Take 100 μL of standard solution of different concentrations to the ELISA plate, add 200 μL CTAB reagent (1.6% w / v), measure the absorbance at 400 nm, draw a standard curve, and calculate the HA concentration of the sample according to the standard curve.

[0072] The results of HA production by different E. coli fermentation are shown in the figure. Figure 4 It can be seen that the HA production of the recombinant engineered bacteria E. coli BL21 (DE3) / pXMJ19-PmHAS / pECXK99E-ugd can reach a level that is distinguishable from the control, and its production is higher than that of E. coli BL21 (DE3) / pXMJ19-PmHAS and E. coli BL21 (DE3) / pXMJ19-PmHAS / pECXK99E-ugd-glmU. Therefore, E. coli BL21 (DE3) / pECXK99E-ugd was subsequently selected as the background strain of the mutant library.

[0073] The pXMJ19-PmHAS mutant plasmid library was transformed into E. coli BL21 (DE3) / pECXK99E-ugd competent cells to obtain the E. coli BL21 (DE3) / pXMJ19-PmHAS / pECXK99E-ugd recombinant engineering bacteria mutant library.

[0074] Example 4 Construction of NNK saturation mutation library and library screening

[0075] The whole plasmid PCR method was used to perform NNK saturation mutagenesis on the K152, P153, G312, E313, N642 and T643 sites of PmHAS, and the primer designs are shown in Table 2 (all described in the 5-3' direction), and the underline represents the mutation site.

[0076] Table 2 Glycine scanning primer design

[0077]

[0078]

[0079] PCR reaction system (50 μL): KOD plus neo 1.0 μL, template 1.0 μL, dNTP 4.0 μL, MgSO4 3.0 μL, 10×KOD buffer 5.0 μL, upstream and downstream primers 1.0 μL each, and ddH2O to make up to 50 μL.

[0080] The PCR amplification program was as follows: (1) denaturation at 95°C for 10 min, (2) denaturation at 94°C for 10 s, (3) annealing at 55°C for 30 s, and (4) extension at 72°C for 3 min 30 s. Steps (2) to (4) were repeated for 35 cycles, and finally extension was performed at 72°C for 10 min. The PCR amplification product was stored at 4°C.

[0081] PCR results are as follows Figure 5 As shown in the figure, the plasmid band of the corresponding size was successfully amplified. Then, DpnI restriction endonuclease was added to the PCR product and incubated at 37°C for 1 hour to remove the template plasmid. After the reaction, 10 μL of the digestion reaction solution was transferred into 100 μL of E. coli BL21 (DE3) / pECXK99E-Ugd competent cells using the CaCl2 / MgCl2 thermal conversion method. After culturing at 37°C for 1 to 1.5 hours, the cells were evenly coated with 5 μg mL -1 Chloramphenicol and 200 μg mL -1 The LB agar plate containing kanamycin was incubated at 37°C for 12 hours. The transformant results were as follows: Figure 6 shown.

[0082] High-throughput screening methods:

[0083] After the transformants grew out, single colonies were picked with toothpicks and inoculated into 96-well deep-well plates containing 300 μL LB liquid medium. After culturing at 37°C and 220 rpm for 12 h, 50 μL of seed solution was transferred to two 48-well deep-well plates containing 1 mL LB liquid medium. After culturing at 37°C and 220 rpm for 2-3 h, IPTG was added at a final concentration of 0.5 mM for induction. The induction temperature was 30°C. After 24 h of induction culture, 500 μL of IPTG at a final concentration of 20 g·L was added to each well. -1 The mixture was added with sterile glucose and cultured at 30°C for 42 h to synthesize HA. After the fermentation was completed, the mixture was centrifuged at 4°C and 4000 rpm for 10 min, the supernatant was discarded, and the collected precipitate was used for HA extraction and concentration determination.

[0084] Use a multichannel pipette to add 500 μL of Solution I to each well of the precipitate obtained above, and perform lysis reaction at 37°C, 220 rpm for 1 hour; then add 500 μL of Solution II and mix gently to completely lyse the cells, and continue to add 750 μL of Solution III for neutralization and precipitation reaction. Then, place the 48-well plate on a centrifuge and centrifuge at 4000 rpm for 20 minutes. Use a multichannel pipette again to draw 1 mL of supernatant into a new 48-well plate, and add 2 mL of anhydrous ethanol to each well, then place it in -20°C for overnight precipitation. The next day, centrifuge it at 4°C, 4000 rpm for 10 minutes, discard the supernatant, and place the precipitate in a drying oven to dry. After drying is complete, add 1 mL of DNAse buffer solution to resuspend the precipitate and wait for HA concentration detection.

[0085] Take 100 μL of the above sample into a 96-well ELISA plate and add 200 μL CTAB (2.5 g·L -1 , 2% NaOH), and then placed on a microplate reader after slight shaking, and the absorbance was measured at 400 nm. 400 Before the formal screening, we determined the precision RSD value of this high-throughput screening method to be 0.26, which represents the fluctuation range of the data in the entire 96-well plate, meaning that mutants with readings 26% higher than the WT readings are likely to be positive mutants, and readings lower than 26% of the WT readings are considered to be fluctuation values ​​between wells. Based on this screening principle, we screened the mutant libraries of the six sites K152, P153, G312, E313, N642 and T643, and the screening results are as follows: Figure 7As shown, 83 mutants were finally obtained, namely 0318-G312-C3, 0318-G312-C5, 0318-G312-C12, 0318-G312-E7, 0318-P153-H8, 0318-T643-C12, 0318-T643-C3, 0318-T643-C4, 0324-E313-C5, 0324-E313-D1, 0324-E313-D7, 0324-E313-E7, 0324-E313-H7, 0324-N642-C9, 0325-K152-B6, 0325-K152-D7, 0325-K153-D8 52-E4, 0325-K152-E5, 0325-K152-F1, 0325-K152-G1, 0325-K152-H1, 0325 -K152-H6, 0325-P153-A7, 0325-P153-A12, 0325-P153-C2, 0325-P153-D7, 0325-P153-E5, 0325-P153-F1, 0325-P153-G2, 0325-P153-G10, 0325-P153 -H1, 0326-G312-B4, 0326-G312-D9, 0326-E313-B1, 0326-E313-D10, 0326-E 313-E4, 0326-E313-E10, 0326-E313-G1, 0326-E313-G4, 0326-E313-G7, 03 26-E313-G8, 0326-E313-G9, 0326-N642-A12, 0326-N642-B3, 0326-N642-B 4. 0326-N642-C4, 0326-N642-E11, 0326-N642-F1, 0326-N642-G2, 0326-N6 42-G12, 0326-N642-H7, 0326-T643-B2, 0326-T643-C2, 0326-T643-E5, 0326 -T643-E8, 0326-T643-G3, 0326-T643-G4, 0326-T643-G11, 0327-P153-A6, 0327-P153-A11, 0327-P153-A12, 0327-P153-B6, 0327-P153-B9, 0327-P15 3-C5, 0327-P153-C6, 0327-P153-E3, 0327-P153-E12, 0327-P153-F12, 032 7-G312-B4, 0327-G312-B5, 0327-G312-C3, 0327-G312-C5 and 0327-G312-F11,0327-T643-B6, 0327-T643-D1, 0327-T643-E8, 0327-T643-E9, 0327-T643-F1, 0327-T643-F3, 0327-T643-F7, 0327-T643-G8 and 0327-T643-G12, these mutants were screened based on meeting OD, 400 (Mutant)>OD 400 (WT)×0.26+OD 400 (WT) or well plate OD 400 (Mutants) ranked in the top 10% or OD 400 (Mutant)>OD 400 (WT)×0.26+OD 400 (WT) and the orifice plate OD 400 (Mutants) ranked in the top 10%.

[0086] Since the number of mutants obtained in the initial screening was large, a secondary screening was required to screen out the better mutants from these mutants. The method of the second round of screening was the same as the above method, except that each mutant was repeated in 3 well plates. The results of the secondary screening are shown in Figure 8 As shown in the figure, a total of 8 mutants, including 0325-K152-E5, 0325-P153-A12, 0325-P153-G2, 0327-P153-A6, 0327-P153-A12, 0327-P153-B9, 0326-E313-B1 and 0318-G312-E7, were obtained, and these mutants will be sequenced later.

[0087] Example 5 Sequence Identification of PmHAS Mutants

[0088] Since the mutant strain screened above contains both pECXK99E-ugd plasmid and pXMJ19-PmHAS mutant plasmid, it is impossible to perform sequence determination by extracting plasmids. It is necessary to design primers to amplify the mutant gene and obtain the gene fragment for sequence identification. The amplification primers are PmHAS-F (SEQ ID NO.13) and PmHAS-R (SEQ ID NO.14), respectively. The PCR amplification system is (50 μL): 1.0 μL of bacterial solution, 25.0 μL of 2×Phanta Master Mix, 1.0 μL of upstream and downstream primers, and ddH2O is added to 50 μL. The PCR amplification procedure was as follows: (1) denaturation at 95°C for 10 min, (2) denaturation at 94°C for 30 s, (3) annealing at 55°C for 30 s, and extension at 72°C for 3 min. Steps (2) to (4) were repeated for 35 cycles, and finally extension was performed at 72°C for 10 min. The PCR amplification product was stored at 4°C. After the PCR was completed, the PCR product was identified by agarose gel electrophoresis. The PCR results were shown in the table below. Fig. 9 As shown in the figure, the PmHAS gene bands were successfully amplified, and then the above products were purified and recovered using a column recovery and purification kit, and sent to Suzhou Hongxun Biotechnology Co., Ltd. for sequence determination. The sequencing results showed that 0325-K152-E5, 0325-P153-A12, 0325-P153-G2, 0327-P153-A6, 0327-P153-A12, 0327-P153-G2, 0327-P153-A6, 0327-P153-A12, 0327-P1 The sequencing results of the eight PmHAS mutants, 53-B9, 0326-E313-B1 and 0318-G312-E7, were as follows: K152 did not mutate, P153S, P153D, P153S, P153 synonymous mutation, P153 did not mutate, E313M and G312S, that is, four mutants, P153S, P153D, E313M and G312S, were finally obtained. The sequencing results are shown in Fig.10 shown.

[0089] Table 3 Gene amplification primers

[0090]

[0091] Example 6 Shake flask fermentation verification of recombinant Escherichia coli mutants

[0092] The four mutants obtained from the above rescreening were again subjected to the third round of shake flask fermentation culture to verify and compare their HA production to screen out the best mutant. The specific steps are: the mutants and control bacteria were streaked to the chloramphenicol (5 μg mL -1 ) and kanamycin (200 μg mL -1) on LB agar plates, cultured overnight at 37°C, 220rpm, and picked a single colony the next day to inoculate into 30mL LB liquid culture medium, cultured at 37°C, 220rpm for 8-10h, and then inoculated into 30mL LB liquid culture medium at a 3% inoculum volume, and continued to culture at 37°C, 220rpm for 2-3h, and wait until OD 600 When the concentration reached 0.8-1.0, IPTG was added to induce the mixture at a final concentration of 0.5 mM. After culturing at 30°C and 220 rpm for 24 h, 20 g·L -1 The culture was continued at 30°C and 220 rpm for 42-48 h for the synthesis of HA. After the fermentation was completed, the extraction, yield and molecular weight of HA were determined by the method described in Example 3.

[0093] The results of the determination of HA concentration of PmHAS mutants are shown in Fig.11 As shown in the figure, the HA production of PmHAS mutants P153S, P153D and G312S is significantly improved compared with WT, which is 2.3, 2.4 and 2.0 times that of WT respectively. At the same time, their weight-average molecular weight is also measured, among which the weight-average molecular weight of WT is 380,000 Da, and the distribution coefficient is 7.8; the weight-average molecular weight of mutant P153S is 440,000 Da, and the distribution coefficient is 7.7; the weight-average molecular weight of P153D is 470,000 Da, and the distribution coefficient is 6.2; the weight-average molecular weight of G312S is 350,000 Da, and the distribution coefficient is 6.4. It can be concluded that mutants P153S and P153D significantly increase HA production and molecular weight, while mutant G312S significantly increases HA production, and the effect on molecular weight is not significant, which means that the co-evolution of HA production and molecular weight is successfully achieved through the transformation method.

[0094] Table 4 Determination of weight average molecular weight of Escherichia coli recombinant engineering bacteria

[0095]

[0096]

[0097] Example 7 Construction of pXMJ19-PmHAS optimal mutation plasmid

[0098] In order to verify the effect of PmHAS mutant plasmid in synthesizing HA in Corynebacterium glutamicum, it is necessary to construct the above mutant plasmids separately and transform them into Corynebacterium glutamicum ATCC13032 competent cells respectively. We used the whole plasmid PCR method to construct the mutant plasmid, PCR reaction system (50μL): KOD plus neo 1.0μL, template 1.0μL, dNTP 4.0μL, MgSO43.0μL, 10×KOD buffer 5.0μL, upstream and downstream primers (Table 5, SEQ ID NO.15-22) 1.0μL each, ddH2O is supplemented to 50μL.

[0099] Table 5 Primers for constructing mutant plasmids

[0100]

[0101] The PCR amplification program was as follows: (1) denaturation at 95°C for 10 min, (2) denaturation at 94°C for 10 s, (3) annealing at 55°C for 30 s, and (4) extension at 72°C for 3 min 30 s. Steps (2) to (4) were repeated for 35 cycles, and finally extension was performed at 72°C for 10 min. The PCR amplification product was stored at 4°C.

[0102] PCR results are as follows Fig.12 As shown in the figure, the plasmid band of the corresponding size was successfully amplified. Then, Dpn I restriction endonuclease was added to the PCR product and incubated at 37°C for 1 hour to remove the template plasmid. After the reaction was completed, 10 μL of the digestion reaction solution was transferred into 100 μL of E. coli BL21 (DE3) competent cells by heat shock transformation method. After culturing at 37°C for 1 to 1.5 hours, it was evenly spread on a plate containing 5 μg mL -1 Chloramphenicol LB agar plates were inverted and cultured at 37°C for 12 hours. After transformants grew out, they were picked for culture, plasmid extraction and sequence determination. The plasmid with the correct sequencing result was the successfully mutated plasmid.

[0103] Example 8 Construction of recombinant Corynebacterium glutamicum containing pXMJ19-PmHAS mutant

[0104] 3 μL of the four pXMJ19-PmHAS mutant plasmids and pXMJ19-PmHAS WTThe plasmids were added to the competent cells of Corynebacterium glutamicum ATCC13032, mixed by pipetting and blowing, and incubated on ice for 30 minutes. The BIO-RAD Micro Pulser electroporator was used, and a 0.2 cm electroporation cup was selected for transformation. The electric shock voltage was 2.5 kV, the time was 4.0 ms, and the electric shock was repeated twice. After the electric shock, it was placed on ice, and 800 μL LB-His medium was quickly added. After resuspending by pipetting, the bacterial solution was aspirated and placed in a centrifuge tube, and shaken and cultured in a shaker at 37°C for 2 hours. After that, the bacterial solution was spread on an LB-His plate containing chloramphenicol resistance. The grown transformants were Corynebacterium glutamicum containing the recombinant plasmid, such as Fig.13 Afterwards, pick a single colony and inoculate it into LB liquid culture medium, and take an appropriate amount of bacterial liquid for storage the next day.

[0105] Example 9 Comparison of hyaluronic acid production of recombinant Corynebacterium glutamicum containing PmHAS mutants

[0106] The recombinant Corynebacterium glutamicum mutants obtained in Example 8 were fermented and cultured in turn to compare the hyaluronic acid yields. Different recombinant Corynebacterium glutamicum mutants and wild bacteria were inoculated into BHI medium, and cultured overnight at 37°C in a shaking incubator as seed culture medium. The seed culture medium was then inoculated into 100 mL of fermentation medium containing 10 g·L corn flour at an inoculum rate of 2%. -1 , anhydrous glucose 30g·L -1 , K2HPO4 0.5g·L -1 , KH2PO4 1.0g·L -1 , NaNO3 15g·L -1 ,MnSO4·H2O1.0g·L -1 , FeSO4·7H2O 0.5g·L -1 , (NH4)2SO4 0.5g·L -1 , 0.1% chloramphenicol (50 mg mL -1 ) in a 500 mL conical flask at 30 °C and 180 rpm min -1 After 2-3 hours of fermentation, IPTG with a final concentration of 0.5 mM was added for induction. After the fermentation was completed, samples were taken to extract HA and determine its content according to the method described in Example 2.

[0107] The results of HA content determination are as follows Fig.14 As shown in the figure, the HA production of mutants P153S, P153D and G312S was significantly higher than that of WT, which were 2.3, 2.3 and 2.6 times that of WT respectively. Among them, the best mutant was G312S, with an HA production of 1.88 g·L -1, followed by mutants P153S and P153D, with HA production reaching 1.69 and 1.68 g·L -1 , and their weight average molecular weights were measured at the same time, as shown in Table 6. As can be seen from the table, the weight average molecular weight of WT is 50,000 Da, and the distribution coefficient is 6.3; the weight average molecular weight of mutant P153S is 100,000 Da, and the distribution coefficient is 8.4; the weight average molecular weight of P153D is 140,000 Da, and the distribution coefficient is 3.5; the weight average molecular weight of G312S is 210,000 Da, and the distribution coefficient is 4.4. It can be concluded that mutants P153S, P153D and G312S all significantly increased HA production and molecular weight, among which the molecular weight of mutant G312S increased to 4 times that of WT, and the HA molecular weight distribution range was more concentrated than WT, which means that the co-evolution of HA production and molecular weight in Corynebacterium glutamicum was successfully achieved through the transformation method.

[0108] It is worth noting that the molecular weight of HA synthesized by PmHAS and its mutants in the Corynebacterium glutamicum host is slightly lower than that of HA synthesized by Escherichia coli. This may be due to the fact that we simultaneously overexpressed the UDP-glucose-6-phosphate-dehydrogenase gene ugd in the Escherichia coli host, and we did not additionally express the ugd gene in Corynebacterium glutamicum, which is considered to be a key gene controlling the molecular weight of HA because it determines whether there is a balance between the two precursors of HA. Therefore, we infer that the concentration of the precursor UDP-GlcA in Corynebacterium glutamicum may be lower than that of UDP-GlcNAc, resulting in a relatively low overall molecular weight, which can be improved by overexpressing the ugd gene or by culturing in a fermenter and accumulating more precursor UDP-GlcA by adding high-concentration glucose during the fermentation process.

[0109] Table 6 Determination of weight average molecular weight of recombinant engineering bacteria of Corynebacterium glutamicum

[0110]

[0111] Example 10 5L fermentation tank process of Corynebacterium glutamicum recombinant engineering bacteria

[0112] We obtained the optimal engineering bacteria ATCC13032 / pXMJ19-PmHAS G312S and control strain ATCC13032 / pXMJ19-PmHAS WT The differences in HA yield and molecular weight at the fermentation tank level were compared by fermentation culture in 5L fermentation tanks. The seed culture medium was BHI and the fermentation medium was anhydrous glucose 30 g·L -1 , ammonium sulfate 30g·L -1 , corn flour 10g·L -1, potassium dihydrogen phosphate 1g·L -1 , potassium hydrogen phosphate 0.5 g·L -1 , Manganese sulfate monohydrate 6.1mg·L -1 , ferrous sulfate heptahydrate 10mg·L -1 , magnesium sulfate heptahydrate 0.5 g·L -1 , L-glutamic acid 1.5 g·L -1 , L-arginine 0.5 g·L -1 .

[0113] First, the engineered bacteria ATCC13032 / pXMJ19-PmHAS G312S and ATCC13032 / pXMJ19-PmHAS WT The line contains chloramphenicol (5 μg mL -1 ) on BHI medium at 30°C for 48 h, and then pick a single colony to add chloramphenicol (5 μg mL -1 ) in BHI liquid medium for 24 h, so that OD 600 When the OD reaches 10-15, inoculate 10% of the inoculum into a 5L fermenter containing 2L of fermentation medium for fermentation. 600 When the concentration reached 10-15, IPTG was added at a final concentration of 0.5 mM for induction at a temperature of 25-30 °C. During the fermentation process, the pH was adjusted by 50% ammonia water to maintain the pH at about 7.0. The dissolved oxygen level was controlled at about 30% by adjusting the stirring speed. The glucose concentration in the fermentation broth was maintained at 10 g·L by adding 50% glucose in batches. -1 During the fermentation process, samples were taken to determine the HA production and molecular weight. The results are shown in Table 7. As can be seen from the table, with the extension of fermentation time, the HA production of the two engineered bacteria gradually increased, but ATCC13032 / pXMJ19-PmHAS WT The HA production of the HA can only reach 1.2 g·L after 52 h of fermentation. -1 , HA molecular weight is only 18,000 Da; while the engineered bacteria ATCC13032 / pXMJ19-PmHAS G312S The HA yield can reach 8.2 g·L after 52 h of fermentation. -1 , which is 6.8 times that of the wild type. The HA molecular weight gradually increases with the extension of fermentation time. At 52h, the HA molecular weight can be as high as 1.15 million Da, which is 63.8 times that of the wild type. The molecular weight is significantly improved, which once again proves that the co-evolution of HA yield and molecular weight is successfully achieved through the transformation method of the patent of this invention.

[0114] Table 7 Fermentation yield and molecular weight of recombinant engineering bacteria of Corynebacterium glutamicum

[0115]

[0116]

[0117] In summary, the present invention provides a protein modification method based on semi-rational design of molecular dynamics simulation to improve the catalytic activity of hyaluronic acid synthase from Pasteurella multocida, and significantly improve the hyaluronic acid yield and molecular weight after fermentation in Escherichia coli and Corynebacterium glutamicum, respectively, and realize the co-evolution of HA yield and molecular weight for the first time, which has a good prospect for industrial application. The patent of this invention also shows that the yield and molecular weight of hyaluronic acid can be significantly improved by protein modification, and this method is also applicable to the modification of other engineered bacteria.

[0118] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limitations of the present invention. In addition, the various modifications listed herein and the variations of methods and compositions in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications obvious to those skilled in the art as described above to obtain the invention should be included within the scope of the present invention.

Claims

1. A type II hyaluronan synthase mutant, It is characterized in that The type II hyaluronan synthase mutant is obtained by mutating any one or several sites of the three regions 150-155, 310-313 or 639-643 on the amino acid sequence of PmHAS.

2. The type II hyaluronan synthase mutant according to claim 1, It is characterized in that The mutant is obtained by mutating any one or several of the K152, P153, G312, E313, N642 or T643 sites.

3. The type II hyaluronan synthase mutant according to claim 2, It is characterized in that The mutant is any one of P153S, P153D or G312S.

4. A gene, It is characterized in that The gene encodes the type II hyaluronan synthase mutant according to claim 1.

5. A plasmid, It is characterized in that The plasmid contains the gene as claimed in claim 4.

6. A bioengineered bacterium, It is characterized in that The bioengineered bacteria contains the plasmid as claimed in claim 5.

7. The bioengineering bacteria according to claim 6, It is characterized in that The bioengineering bacteria are Escherichia coli or Corynebacterium glutamicum.

8. Use of the type II hyaluronan synthase mutant according to any one of claims 1 to 3, the gene according to claim 4, the plasmid according to claim 5, or the bioengineering bacteria according to any one of claims 6 to 7 in the preparation of hyaluronic acid.

9. A method for preparing type II hyaluronic acid, the method include: Constructing bioengineering bacteria containing the target gene, culturing and fermenting the bioengineering bacteria, and obtaining fermentation products; The target gene is obtained by mutating any one or more sites in the three regions of 150-155, 310-313 or 639-643 on the PmHAS amino acid sequence.

10. The method according to claim 9, It is characterized in that The target gene is a gene in which the amino acid sequence of PmHAS is mutated into any one of P153S, P153D or G312S.

Citation Information

Cited By

  • Ultrahigh molecular weight hyaluronic acid synthetase mutant as well as construction method and application thereof

    CN121294386A